Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Poxel S.A. (POXEL.PA)
Lyon, FR
Poxel S.A. is a clinical-stage biopharmaceutical firm dedicated to discovering innovative therapies for a range of conditions, including metabolic disorders, type 2 diabetes, and liver ailments. Its most advanced investigational drug, Imeglimin, is an oral medication candidate for type 2 diabetes. This treatment has successfully completed Phase III trials in Japan and is currently undergoing Phase III development in both the United States and Europe. Imeglimin works by enhancing pancreatic beta cell function, reducing insulin resistance, and mitigating significant cardiovascular and metabolic risk factors like elevated blood lipid levels and excessive body weight. Beyond Imeglimin, Poxel is also advancing PXL770, an activator of the adenosine monophosphate-activated protein kinase (AMPK) enzyme. This compound is presently in a Phase 2a clinical trial, targeting various chronic metabolic diseases, notably those affecting the liver, such as non-alcoholic steatohepatitis (NASH). Furthermore, the company has strategic collaborations for other pipeline assets. Under a licensing agreement with Enyo Pharma S.A.S., Poxel is developing PXL007 (also known as EYP001), a synthetic non-steroidal and non-bile acid FXR agonist, which is currently in a Phase II study for treating hepatitis B and NASH. Another partnership with DeuteRx LLC focuses on PXL065, a mitochondrial pyruvate carrier inhibitor, now in a Phase I clinical trial specifically for NASH. Established in 2009, Poxel S.A. operates from its headquarters in Lyon, France.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.72% | -2.55% | -10.89% | -14.87% | -11.24% | -2.14% | -70.57% | -63.06% | -96.84% | -98.25% | -96.82% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 1 | 0 |
| Hold | 1 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+235.0% ★ Q2'25: +128.6% (vs Q2'23)
-
EPS growth Biotechnology: +29.7%+58.2% ★ Q2'25: +93.9% (vs Q2'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-101.9% Q2'25: +345.2% (vs Q2'23)
-
EBIT margin Biotechnology: +0.0%-67.0% Q2'25: -113.2% (vs Q2'23)
-
ROIC Biotechnology: -16.1%-62.5% Q2'25: +334.8% (vs Q2'23)
-
Share dilution Biotechnology: -3.4%+23.6% Q2'25: +62.1% (vs Q2'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-16.13× Q2'25: -6.17× (vs Q2'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
59.7K
est: 1.00M (-94.0%)
|
5.29M
est: 22.07M (-76.0%)
|
74.61M
est: 74.60M (+0.0%)
|
26.56M
est: 32.30M (-17.8%)
|
6.81M
est: 6.70M (+1.6%)
|
13.40M
est: 30.20M (-55.6%)
|
674.0K
est: 4.35M (-84.5%)
|
1.98M
est: 1.98M (+0.0%)
|
6.64M
est: 6.64M (+0.0%)
|
11.60M
est.
|
| EBITDA |
-11.31M
est: -930.3K (-1,116.2%)
|
-21.87M
est: -20.53M (-6.5%)
|
-2.81M
est: -69.40M (+96.0%)
|
-25.28M
est: -30.05M (+15.9%)
|
-29.72M
est: -6.23M (-376.7%)
|
-22.52M
est: -28.09M (+19.8%)
|
-28.02M
est: -4.05M (-592.5%)
|
-12.17M
est: -1.84M (-560.5%)
|
-4.32M
est: -6.17M (+30.0%)
|
-10.79M
est.
|
| EBIT |
-11.38M
est: -934.1K (-1,118.8%)
|
-22.25M
est: -20.61M (-8.0%)
|
1.41M
est: -69.68M (+102.0%)
|
-25.70M
est: -30.17M (+14.8%)
|
-30.24M
est: -6.26M (-383.2%)
|
-23.08M
est: -28.21M (+18.2%)
|
-28.58M
est: -4.06M (-603.3%)
|
-29.38M
est: -1.85M (-1,487.6%)
|
-4.45M
est: -6.20M (+28.2%)
|
-10.84M
est.
|
| Net Income |
-12.24M
est: -31.02M (+60.5%)
|
-22.69M
est: -5.48M (-314.2%)
|
13.53M
est: 5.23M (+158.5%)
|
-25.74M
est: -31.02M (+17.0%)
|
-31.86M
est: -51.26M (+37.8%)
|
-23.76M
est: -26.73M (+11.1%)
|
-31.40M
est: -49.64M (+36.7%)
|
-35.09M
est: -42.95M (+18.3%)
|
-18.31M
est: 43.91M (-141.7%)
|
-59.18M
est.
|
| SGA |
2.68M
est: 2.47M (+8.6%)
|
3.45M
est: 54.43M (-93.7%)
|
4.49M
est: 184.03M (-97.6%)
|
7.41M
est: 79.68M (-90.7%)
|
9.94M
est: 16.53M (-39.9%)
|
10.63M
est: 74.50M (-85.7%)
|
4.44M
est: 10.73M (-58.6%)
|
5.03M
est: 4.89M (+2.9%)
|
6.35M
est: 16.37M (-61.2%)
|
28.62M
est.
|
| EPS |
-0.68
est: -0.65 (-4.6%)
|
-0.99
est: -0.11 (-762.3%)
|
0.54
est: 0.11 (+392.7%)
|
-0.99
est: -0.65 (-52.3%)
|
-1.16
est: -1.07 (-8.0%)
|
-0.83
est: -0.56 (-48.2%)
|
-1.08
est: -1.04 (-3.8%)
|
-0.91
est: -0.90 (-1.1%)
|
-0.38
est: 0.92 (-141.3%)
|
-1.24
est.
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Arthur Rouille | Investor Relations Officer | — | male |
| Fanny Bosa | Vice President of Finance & Administration | — | female |
| Nicolas Trouche | Chief Executive Officer & Director | — | male |
| Sylvie Bertrand | Senior Vice President of Human Resources | — | female |
| Tejdeep Bawa | Vice President & Head of Business Development | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for POXEL.PA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
